$VRNA
Verona Pharma PLC Stock $vrna

$vrna Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000165731222000016 Filed on May 03, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.440M	$9.280M
YoY Change	-19.83%	36.87%
% of Gross Profit
Research & Development	$17.63M	$13.57M
YoY Change	29.84%	78.09%
% of Gross Profit
Depreciation & Amortization	$163.0K	$153.0K
YoY Change	6.54%	-4.38%
% of Gross Profit
Operating Expenses	$25.07M	$22.86M
YoY Change	9.66%	57.8%
Operating Profit	-$25.07M	-$22.86M
YoY Change	9.66%	57.8%
Interest Expense	$84.00K	$84.00K
YoY Change	0.0%
% of Operating Profit
Other Income/Expense, Net	$310.0K	$1.646M
YoY Change	-81.17%	-24.81%
Pretax Income	-$24.76M	-$21.21M
YoY Change	16.71%	72.51%
Income Tax	$82.00K	$80.00K
% Of Pretax Income
Net Earnings	-$24.84M	-$21.29M
YoY Change	16.66%	72.44%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.05	-$0.05
Diluted Earnings Per Share	-$0.05	-$0.05
COMMON SHARES
Basic Shares Outstanding	481.9M shares	469.5M shares
Diluted Shares Outstanding	481.9M shares	469.5M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$132.8M	$169.6M
YoY Change	-21.72%	557.36%
Cash & Equivalents	$132.8M	$169.6M
Short-Term Investments
Other Short-Term Assets	$2.525M	$1.484M
YoY Change	70.15%	-38.17%
Inventory
Prepaid Expenses	$1.246M	$7.247M
Receivables
Other Receivables
Total Short-Term Assets	$153.0M	$188.6M
YoY Change	-18.9%	383.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$71.00K	$98.00K
YoY Change	-27.55%	-93.88%
Goodwill	$545.0K	$545.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments	$15.00M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$16.36M	$1.549M
YoY Change	956.17%	-71.84%
TOTAL ASSETS
Total Short-Term Assets	$153.0M	$188.6M
Total Long-Term Assets	$16.36M	$1.549M
Total Assets	$169.3M	$190.2M
YoY Change	-10.96%	327.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.064M	$541.0K
YoY Change	1390.57%	-93.4%
Accrued Expenses	$28.88M	$8.514M
YoY Change	239.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$37.90M	$12.70M
YoY Change	198.5%	26.98%
LONG-TERM LIABILITIES
Long-Term Debt	$4.900M	$4.700M
YoY Change	4.26%	370.0%
Other Long-Term Liabilities	$177.0K	$400.0K
YoY Change	-55.75%	-73.33%
Total Long-Term Liabilities	$5.105M	$5.038M
YoY Change	1.33%	101.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$37.90M	$12.70M
Total Long-Term Liabilities	$5.105M	$5.038M
Total Liabilities	$43.01M	$17.74M
YoY Change	142.49%	41.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$288.7M	-$228.4M
YoY Change	26.4%
Common Stock	$32.18M	$31.79M
YoY Change	1.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$739.0K	$1.670M
YoY Change	-55.75%
Treasury Stock Shares
Shareholders Equity	$126.3M	$172.4M
YoY Change
Total Liabilities & Shareholders Equity	$169.3M	$190.2M
YoY Change	-10.96%	327.3%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$24.84M	-$21.29M
YoY Change	16.66%	72.44%
Depreciation, Depletion And Amortization	$163.0K	$153.0K
YoY Change	6.54%	-4.38%
Cash From Operating Activities	-$14.51M	-$18.55M
YoY Change	-21.77%	40.28%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$67.00K	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$726.0K	$0.00
YoY Change
NET CHANGE
Cash From Operating Activities	-$14.51M	-$18.55M
Cash From Investing Activities	$0.00	$0.00
Cash From Financing Activities	-$726.0K	$0.00
Net Change In Cash	-$15.62M	-$18.39M
YoY Change	-15.08%	237.7%
FREE CASH FLOW
Cash From Operating Activities	-$14.51M	-$18.55M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$14.51M	-$18.55M
YoY Change	-21.77%	40.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001657312
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-38067
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Verona Pharma plc
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1489389
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 More London Riverside
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	London
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	SE1 2RE
CY2022Q1	dei	Entity Address Country EntityAddressCountry	GB
CY2022Q1	dei	Country Region CountryRegion	44
CY2022Q1	dei	City Area Code CityAreaCode	203
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	283 4200
CY2022Q1	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.05 per share*
CY2022Q1	dei	Trading Symbol TradingSymbol	VRNA
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	482944390	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132764000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148380000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1246000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4037000	USD
CY2022Q1	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	16420000	USD
CY2021Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	15583000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	2525000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2063000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	152955000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	170063000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	71000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	545000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	545000	USD
CY2022Q1	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10044000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28877000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	744000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	899000	USD
CY2022Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	16360000	USD
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	16524000	USD
CY2022Q1	us-gaap	Assets Assets	169315000	USD
CY2021Q4	us-gaap	Assets Assets	186587000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8064000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22256000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	583000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	648000	USD
CY2022Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	235000	USD
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	147000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	144000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	327000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	37903000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	33422000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4928000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4874000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	177000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	286000	USD
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5105000	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5160000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	43008000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	38582000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	494058246	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	489177550	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	482944390	shares
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	603000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	USD
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	480082966	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	32182000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	31855000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	388204000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	385070000	USD
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	739000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288739000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-263716000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	126307000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	148005000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	169315000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	186587000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17625000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13574000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7440000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9282000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	25065000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	22856000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25065000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-22856000	USD
CY2022Q1	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	1302000	USD
CY2021Q1	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	2070000	USD
CY2022Q1	us-gaap	Investment Income Net InvestmentIncomeNet	15000	USD
CY2021Q1	us-gaap	Investment Income Net InvestmentIncomeNet	4000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	84000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	84000	USD
CY2022Q1	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	0	USD
CY2021Q1	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	-507000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	82000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	80000	USD
CY2022Q1	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	-923000	USD
CY2021Q1	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	163000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	310000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1646000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24755000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21210000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24837000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-21290000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	148005000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24837000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67000	USD
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	793000	USD
CY2022Q1	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	-118000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3747000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	126307000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	184854000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-21290000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8850000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	172414000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24837000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-21290000	USD
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1119000	USD
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	155000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	23000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	19000	USD
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	31000	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	31000	USD
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	507000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3748000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8850000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	163000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	153000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2791000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2709000	USD
CY2022Q1	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	1578000	USD
CY2021Q1	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	2012000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	462000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-236000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1980000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	363000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6621000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2349000	USD
CY2022Q1	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-174000	USD
CY2021Q1	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-210000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	88000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	0	USD
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-65000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	15000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14512000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18551000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	793000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-726000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-378000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	163000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15616000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18388000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148380000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187986000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132764000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	169598000	USD
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	53000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	55000	USD
CY2022Q1	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288700000	USD
CY2022Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	80696	shares
CY2022Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.86
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	60576894	shares
CY2022Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	100000	USD
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation, the fair value of warrants, research and development tax credit and the carrying value of the equity interest in Nuance Pharma (as defined below). Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates.</span></div>
CY2022Q1	vrna	Prepaid Research And Development Fees Current PrepaidResearchAndDevelopmentFeesCurrent	452000	USD
CY2021Q4	vrna	Prepaid Research And Development Fees Current PrepaidResearchAndDevelopmentFeesCurrent	2169000	USD
CY2022Q1	us-gaap	Prepaid Insurance PrepaidInsurance	435000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1555000	USD
CY2022Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	359000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	313000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1246000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4037000	USD
CY2022Q1	vrna	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	16420000	USD
CY2021Q4	vrna	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	15583000	USD
CY2022Q1	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	16420000	USD
CY2021Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	15583000	USD
CY2022Q1	vrna	Gain Loss From Research And Development Tax Credit Excluding Annual Cap GainLossFromResearchAndDevelopmentTaxCreditExcludingAnnualCap	3600000	USD
CY2022Q1	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	1300000	USD
CY2022Q1	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	27520000	USD
CY2021Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	21336000	USD
CY2022Q1	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	846000	USD
CY2021Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	919000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	511000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28877000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22256000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4900000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3748000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12695200	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.38
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8850000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	608000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.62
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13303200	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.34
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	77584846	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24837000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-21290000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	481941527	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	481941527	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	469465085	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	469465085	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05

Files In Submission

Name	View Source	Status
0001657312-22-000016-index-headers.html	Edgar Link	pending
0001657312-22-000016-index.html	Edgar Link	pending
0001657312-22-000016.txt	Edgar Link	pending
0001657312-22-000016-xbrl.zip	Edgar Link	pending
exhibit311q122.htm	Edgar Link	pending
exhibit312q122.htm	Edgar Link	pending
exhibit321q122.htm	Edgar Link	pending
exhibit322q122.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
svb-second_amendmentxtox.htm	Edgar Link	pending
svb-second_amendmentxtox001.jpg	Edgar Link	pending
svb-second_amendmentxtox002.jpg	Edgar Link	pending
svb-second_amendmentxtox003.jpg	Edgar Link	pending
svb-second_amendmentxtox004.jpg	Edgar Link	pending
vrna-20220331.htm	Edgar Link	pending
vrna-20220331.xsd	Edgar Link	pending
vrna-20220331_cal.xml	Edgar Link	unprocessable
vrna-20220331_def.xml	Edgar Link	unprocessable
vrna-20220331_htm.xml	Edgar Link	completed
vrna-20220331_lab.xml	Edgar Link	unprocessable
vrna-20220331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRNA
Verona Pharma PLC Stock $vrna

2022 Q1 Form 10-Q Financial Statement

#000165731222000016 Filed on May 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA Verona Pharma PLC Stock $vrna

2022 Q1 Form 10-Q Financial Statement

#000165731222000016 Filed on May 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA
Verona Pharma PLC Stock $vrna